(NASDAQ: TTRX) Turn Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.15%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.17%.
Turn Therapeutics's earnings in 2026 is -$3,836,501.On average, 3 Wall Street analysts forecast TTRX's earnings for 2026 to be -$3,646,056, with the lowest TTRX earnings forecast at -$3,503,074, and the highest TTRX earnings forecast at -$3,753,293. On average, 3 Wall Street analysts forecast TTRX's earnings for 2027 to be -$10,938,168, with the lowest TTRX earnings forecast at -$10,509,221, and the highest TTRX earnings forecast at -$11,259,879.
In 2028, TTRX is forecast to generate -$5,165,246 in earnings, with the lowest earnings forecast at -$4,962,687 and the highest earnings forecast at -$5,317,165.